-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Initiates Coverage On Sagimet Biosciences with Buy Rating, Announces Price Target of $27

Benzinga·02/03/2026 16:35:45
Listen to the news
Guggenheim analyst Seamus Fernandez initiates coverage on Sagimet Biosciences (NASDAQ:SGMT) with a Buy rating and announces Price Target of $27.